Episode: 82 - PANEL DISCUSSION: Future of Biologic Therapeutics: Will Half-Life Extended Peptides Replace Multispecific Antibodies?
About this episode
A panel of industry experts discusses the future of biologic therapeutics, focusing on the potential of half-life extended peptides versus multispecific antibodies.
During last year’s PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics, followed by a conversation featuring Paul Carter, Ph.D., Genentech Fellow of Antibody Engineering, G. Jonah Rainey, Ph.D., associate vice president of Eli Lilly and Company, and Janine Schuurman, Ph.D., biotech consultant at Lust for Life Science B.V. Moderate...
Topics covered
- biologic therapeutics
- monoclonal antibodies
- peptides
- antibody engineering
- biotechnology
More episodes of The Chain: Protein Engineering Podcast
- Episode: 85 - Daniel Chen on Building Multi-Target Drugs with Logic Gating
- Episode: 83 - Patrick Baeuerle and Jeffrey Miller on T Cell and Immune Cell Engagement
- Episode: 81 - Laszlo Radvanyi on Pushing Boundaries in Cancer Immunotherapy Research
- Episode: 80 - Vibha Jawa Discusses the Impact of Biologic Molecules and the Future of Immunogenicity
- Episode: 79 - Conversation with Bahija Jallal on the Biggest Anticipated Transformations and Breakthroughs
- Episode: 78 - Shamit Shrivastava on an Interdisciplinary Approach to Antibody Biophysics and Developability
Explore listener stats, chart rankings, contacts and more on the The Chain: Protein Engineering Podcast podcast page.